61 matches for your search in the start-up spotlight
rss
Isomorphic Labs announces $600m external investment round
03-Apr-2025
Isomorphic Labs, an AI-first drug design and development company, announced it has raised $600 Million in its first external funding round. The financing round is led by Thrive Capital, with participation from GV, and follow-on capital from existing investor, Alphabet. Isomorphic Labs was founded ...
University of Oxford spinout accelerates commercial expansion in the US of its innovative stroke AI imaging solution, with its demonstrated impact on vital treatments
25-Mar-2025
Brainomix, a company pioneering AI-powered imaging tools in stroke and lung fibrosis, announced the completion of a £14M ($18M) Series C investment round. The round is co-led by prominent healthtech investors that include existing investors, Parkwalk Advisors, the UK’s largest growth EIS fund ...
Seed funding to accelerate the development of a pipeline for targeted protein degradation
12-Mar-2025
TRIMTECH Therapeutics, a biotech company harnessing targeted protein degradation (TPD) for the treatment of neurodegenerative diseases, announced the closing of its $31 million (£25 million) seed funding round. The financing was led by Cambridge Innovation Capital (CIC) and SV Health Investors’ ...
Infex and Justus-Liebig-University Giessen awarded £1 million grant from PACE
18-Feb-2025
Infex Therapeutics, a leading anti-infectives specialist, announces that in collaboration with Justus-Liebig-University Giessen (“JLU”), Germany it has been awarded a £1 million grant from PACE (Pathways to Antimicrobial Clinical Efficacy), to develop a first-in-class BamA inhibitor targeting ...
Glox Therapeutics awarded share of £3M Collaborative Discovery Programme funding from Cystic Fibrosis Antimicrobial Resistance Syndicate
28-Jan-2025
Glox Therapeutics, a company pioneering the development of precision antibiotic therapies based on naturally occurring bacteriocins, announced it has been awarded a share of the £3 million Collaborative Discovery Programme (CDP) launched by the Cystic Fibrosis Antimicrobial Resistance (CF AMR) ...
Up to 10 times faster drug development expected
11-Dec-2024
UK-based Concept Life Sciences (Concept) and Accelero Biostructures (Accelero) in the US have formed an industry-leading partnership which will help pharma businesses worldwide speed up drug development by up to tenfold. The collaboration accelerates the timeline for progressing from drug ...
Series A financing highlights the potential impact of Abselion’s technology for life science research and bioprocess development
10-Dec-2024
Abselion, an innovator in automated analytical instrumentation that simplifies at-line protein quantification, has secured £6.6 million in Series A financing to bring its award-winning Amperia system to market. This cutting-edge benchtop instrument allows scientists to easily quantify antibodies, ...
Antiverse raises £3.5M
21-Oct-2024
Antiverse, a techbio company designing antibodies for challenging targets, announced it has added £3.5M ($4.6M) to its seed funding. The investment will facilitate the Company’s growth, including appointments to strengthen the team and continued development of its antibody design programmes, many ...
“2024 is our year – we've scaled up three products, secured investor backing, brought new talent onboard and successfully launched our first commercial application"
15-Oct-2024
Floreon was announced the winner of The US Plastics Industry Association’s (PLASTICS) Innovation in Bioplastics Award for its breakthrough plant-based, flame retardant, halogen-free polymer - uniquely suited to high performance engineering applications. The accolade signifies Floreon ...
Electric vehicle range could increase by up to 20 per cent
09-Oct-2024
Integrals power has made a breakthrough in Lithium Manganese Iron Phosphate (LMFP) cathode active materials for battery cells. Applying its propriety materials technology and patented manufacturing process, the company has overcome the drop in specific capacity compared that typically occurs as ...
